Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 2, 1999, Pages 268-274

  Schwieler, Jonas H ^a   Ericsson, Hans ^b   Löfdahl, Per ^c   Thulin, Tomas ^d   Kahan, Thomas ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Hjärtmottagningen Helsingborg   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood pressure; Clevidipine; Dihydropyridine calcium antagonist; Hypertension; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BUTYROXYMETHYLMETHYL 4 (2',3' DICHLOROPHENYL) 2,6 DIMETHYL 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; CALCIUM ANTAGONIST; CLEVIDIPINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCIUM ANTAGONISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TOLERABILITY; EXTRASYSTOLE; HEADACHE; HEART RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HUMANS; HYPERTENSION; MIDDLE AGED; PYRIDINES; SINGLE-BLIND METHOD;

EID: 0032807949     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908000-00013     Document Type: Article

References (19)

1. Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet 1984;9:239-51.
2. Kaplan JA, Finlayson DC, Woodward S. Vasodilator therapy after cardiac surgery: a review of the efficacy and toxicity of nitroglycerin and nitroprusside. Can Anaesth Soc J 1980;27:254-9.
3. Ihlen H, Myhre E, Opstad P. Evaluation of potential adverse effects of sodium nitroprusside during pacing-induced myocardial ischaemia in man. Eur Heart J 1984;5:834-41.
4. Lawrence CJ, Lestrade A, De Lange S. Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery. Acta Anaesthesiol Scand Suppl 1993;37:48-52.
5. Cook E, Clifton GG, Vargas R, et al. Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine. Clin Pharmacol Ther 1990;47:706-18.
6. Levy JH, Huraux C, Nordlander M. Treatment of perioperative hypertension. In: Epstein M, ed. Calcium antagonists in clinical medicine. Philadelphia: Hanely & Belfus, 1997:345-58.
7. Ericsson H, Fakt C, Höglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol 1999;1:61-7.
8. Vuylsteke A, Milner Q, Mur D, Ericsson H, Dunning J, Latimer RD. Therapeutic dose rates and pharmacokinetics of clevidipine in patients undergoing coronary artery bypass surgery. Br J Anaesth 1998;80:A11.
9. Kieler-Jensen N, Jolin-Mellgård Å, Nordlander M, et al. Myocardial circulatory and metabolic effects of clevidipine after coronary artery bypass grafting (CABG). Br J Anaesth 1998;78:A12.
10. Ericsson H, Fakt C, Jolin-Mellgård Å, et al. Clinical and pharmacokinetic results with a new ultrashort acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol 1999;47:531-8.
11. Holm G, Hanssen K, Svensson L. Use of dodecyl sulphate as an esterase inhibitor before gas-chromatographic determination of labile β-adrenoceptor blocking drugs. Clin Chem 1985;31:868-70.
12. Lindmark B, Ahnoff M, Persson BA. Enantioselective LC-MS assays for human pharmacokinetics of felodipine and clevidipine. Swedish Pharmaceutical Congress, Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden, 1997:36.
13. Akaike A. Posterior probabilities for choosing a regression model. Ann Instit Math Stats 1978;30:A9.
14. Scientific Consulting. Professional WinNonlin user's guide. Lexington: Scientific Consulting, 1997.
15. Kleinbloesem CH, Van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD. Rate of increase in plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans. Clin Pharmacol Ther 1987;41:26-40.
16. Brislow SD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969;39:48-54.
17. Kotrly KJ, Ebert TJ, Vucins E, Igler FO, Barney JA, Kampine JP. Baroreceptor reflex control of heart rate during isoflurane anaesthesia in humans. Anesthesiology 1984;60:173-9.
18. Tanaka M, Nishikawa T. Arterial baroreflex function in humans anaesthetised with sevoflurane. Anesthesiology 1997;87:A132.
19. Epstein M, Loutzenhiser R. Calcium antagonists and the kidney. Philadelphia: Hanley & Belfus, 1990.